
South Korean stocks opened lower on Monday despite Wall Street's advance as hopes for a diplomatic breakthrough in the Iran conflict pushed oil prices lower, with KOSPI falling 0.47% to 7,040.76 and major tech stocks mixed.
AI-generated summary
South Korean stocks had been on a winning streak before the Chuseok holiday, while US markets ended higher on Friday led by technology and industrial stocks.
SEOUL, Sept. 28 (Yonhap) -- South Korean stocks opened lower Monday despite Wall Street's advance, as hopes for a diplomatic breakthrough in the Iran conflict pushed oil prices lower.
The benchmark Korea Composite Stock Price Index (KOSPI) fell 40.16 points, or 0.47 percent, to 7,040.76 as of 9:15 a.m.
The KOSPI extended its winning streak to a fourth session Wednesday and was closed Thursday and Friday for the Chuseok holiday, South Korea's equivalent of Thanksgiving.
U.S. stocks ended higher on Friday (local time), with technology and industrial companies leading the gains.
The Dow Jones Industrial Average rose 0.93 percent, the S&P 500 gained 0.51 percent, and the tech-heavy Nasdaq Composite Index advanced 0.48 percent.
Brent crude settled around US$104 a barrel after reports that Iran had proposed a plan to end the conflict.
In Seoul, most market heavyweights traded mixed.
Top market cap Samsung Electronics went down 1.14 percent, and chip giant SK hynix lost 2.63 percent.
SK Square, the parent company of SK hynix, shed 3.36 percent.
In contrast, Samsung Electro-Mechanics, an electronics component affiliate of Samsung Electronics, increased 4.31 percent.
The Korean won was trading at 1,357.1 won against the U.S. dollar, down 0.1 won from the close of the previous stock trading session.
AI outlook โ possibilities, not facts
KOSPI may recover if Iran diplomacy fails to produce concrete results and oil prices rebound
Possible ยท Within weeks

LG Chem Ltd. announced a partnership with Volkswagen Group to jointly develop next-generation eco-friendly mobility materials, focusing on reducing vehicle weight and improving performance using its acrylonitrile butadiene styrene (ABS) and engineering plastics (EP), including post-consumer recycled (PCR) materials.

Gimpo City announced on the 28th that it formed a task force to revitalize Laveniche, which has an artificial waterway and a commercial district, as a representative waterside tourism and commercial space in the region, and discussed ways to discover sustainable businesses led by merchants and establish a private-coexistence council.

As prices of solar modules and polysilicon rise ahead of the enforcement of Article 232 (Section 232) of the U.S. Trade Expansion Act, stock prices of solar energy-related stocks such as Hanwha Solutions and OCI Holdings are rising in early trading. According to Anza, the median price of imported modules rose approximately 40.7% from $0.27 to $0.38 per watt, and the prices of American polysilicon and single crystal perc modules also rose. A researcher at Hana Securities predicted that the price increase will become even steeper after the implementation of Section 232.

Mokpo City and the Korea Institute of Ocean Science and Technology's Ship and Offshore Plant Research Institute (KRISO) collaborated to move the Eco-Friendly Fuel Propulsion Research Center to Mokpo South Port and begin operating it. They announced on the 28th that they plan to use the 30MW electric propulsion system test facility to verify ship performance and safety and support the commercialization of eco-friendly ship technology.

NH Investment & Securities signed a business agreement with Trinity Airlines for cooperation in the International Aviation Carbon Offset and Reduction System (CORSIA) and the greenhouse gas emissions trading system. Trinity Airlines plans to first procure 20,000 tons of CORSIA emissions permits through NH Investment & Securities and secure the quantity in stages ahead of the settlement deadline in January 2028.

Hanall Biopharma's stock price is trading at 43,300 won, down 7.08% in the early trading on the 28th due to the news of partner company Immunovant's cutaneous lupus erythematosus (CLE) clinical trial suspension. Securities companies lowered the target stock price, but maintained a โbuyโ investment opinion, saying that damage to the value of the core new drug is limited.